Ahlstrand C, Tiselius H G
Department of Urology, University Hospital, Linköping, Sweden.
Scand J Urol Nephrol. 1987;21(3):225-8. doi: 10.3109/00365598709180326.
Twelve patients who formed renal stones during acetazolamide treatment for glaucoma were studied. Calcium phosphate was the dominating component in the stones. Long term treatment with acetazolamide decreased urinary citrate markedly, which will result in an increased ion-activity product of calcium phosphate and a decreased inhibiting property of urine on calcium phosphate crystallization. The treatment also increased urinary oxalate which together with a low citrate might increase the risk of calcium oxalate crystallization. However, an estimate of the ion-activity product of calcium oxalate in urine (AP [CaOx]-index) was unaffected by the treatment and calcium oxalate was a minor component of the stones.
对12例在使用乙酰唑胺治疗青光眼期间形成肾结石的患者进行了研究。磷酸钙是结石的主要成分。长期使用乙酰唑胺治疗可显著降低尿枸橼酸盐水平，这将导致磷酸钙的离子活性产物增加，尿液对磷酸钙结晶的抑制作用降低。该治疗还会增加尿草酸盐，低枸橼酸盐水平与尿草酸盐增加可能会增加草酸钙结晶的风险。然而，尿液中草酸钙的离子活性产物估计值（AP[CaOx]指数）不受该治疗影响，且草酸钙是结石的次要成分。
